Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2018 | Bosutinib: a new, safer TKI for frontline CML

Michael Mauro • 1 Jun 2018
ASCO 2018
Chronic Myeloid Leukemia Leukemia Bosutinib Imatinib
BFORE

The recent FDA approval of bosutinib makes it the fourth inhibitor for the frontline treatment of chronic myeloid leukemia (CML), as Michael Mauro, MD, of Memorial Sloan Kettering Cancer Center, New York, NY, tells us in this interview. Dr Mauro explains how bosutinib has a unique safety profile that makes it more desirable than other inhibitors, such as imatinib, and emphasizes its use as a safe, effective inhibitor for CML patients (BFORE; NCT02130557). This interview was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.

More from Michael Mauro

6:31
An overview of trials investigating asciminib in the treatment of Ph+ CML
Michael Mauro • 18 Dec 2023
2:26
ASCEMBL: asciminib versus bosutinib in third-line treatment of CP-CML
Michael Mauro • 18 Dec 2023
1:14
Unmet needs in pediatric CML
Michael Mauro • 22 Oct 2022
1:52
ESH CML session highlights: pediatrics, biomarkers, and COVID
Michael Mauro • 22 Oct 2022

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals